About
Daniel Tsai
Postdoctoral research fellow in pharmacoepidemiology at the Population Health Data Center, NCKU.
BIO
Daniel Tsai is a postdoctoral research fellow at the Population Health Data Center, NCKU. He specialises in comparative effectiveness research and policy research. His expertise includes triangulating claims databases, electronic health records, and biomedical databases to inform causal inference. He is also actively involved in the intersection of artificial intelligence and geriatric medicine. Daniel serves as an educational co-lead of the Asian Pharmacoepidemiology Network (AsPEN) and is an active member of the Neurological and Mental Health Global Epidemiology Network (NeuroGEN), where he contributes to fostering international research collaboration and advancing pharmacoepidemiology.
Education
- Aug 2023 – Jul 2026
PhD, Pharmacoepidemiology
National Cheng Kung University
- Aug 2019 – Jul 2021
MClinPharm, Clinical Pharmacy
National Cheng Kung University
- Sep 2014 – Jun 2019
BS, Pharmacy
China Medical University
Experience
- May 2024 – present
Research Fellow & Operations/Technology Lead
Population Health Data Center, NCKU, Taiwan
- Aug 2021 – Jul 2024
Research Data Analyst
Centre for Neonatal and Paediatric Infection, St George's, University of London, UK
- Sep 2019 – Jul 2021
Clinical Pharmacist
National Cheng Kung University Hospital, Taiwan
Training & skills
Computing: Proficient in SAS, Stata, SPSS, and R, with extensive experience across the entire data pipeline — extraction, cleaning, analysis, and visualization. I conduct large-scale pharmacoepidemiologic studies and triangulate study designs using the Taiwan National Health Insurance Database (20M+ individuals). This work has supported complex designs and advanced statistical analyses published in journals including BMJ, Nature Communications, CMAJ, JAMA Network Open, PLOS Medicine, and BMC Medicine.
Clinical Pharmacist (Licensed in Taiwan; MoHW No. 045275): nephrology-ward service covering antibiotic stewardship, medication reconciliation, renal pharmacotherapy optimization, therapeutic drug monitoring, adverse drug reaction prevention, and patient education within a multidisciplinary team.
Grants & awards
Contributor to projects funded by industry (Amgen, Clarivate, Prospection) and government (Taiwan's National Science and Technology Council, National Institutes of Health, Ministry of Education), focused on real-world evidence, pharmacoepidemiology, and causal inference. Recognised by multiple ISPE travel/registration scholarships for ICPE (2021–2023), ISPE (2024–2025), and ACPE (2021–2025).
Award: ISPE-Asian Conference on Pharmacoepidemiology 15 — Rising Star.
Selected publications
View all publications →33 publications · 368 citations · h-index 9 (Google Scholar, 2026-10-19)
-
Data InfrastructureHsieh CY, Shao SC, Sung SF, Hsieh MHC, Tsai DHT, Lin SJ, Lai ECC. Taiwan's National Health Insurance Research Database (NHIRD): in the Era of Artificial Intelligence, Causal Inference, and Data Security. Clinical Epidemiology. 2025 Nov 25;17:967-981.
-
Global Disease BurdenTsai DHT, Wu ICY, Chang LF, Lu MJH, Debnath B, Govender NP, Sharland M, Warris A, Hsia Y, Ferreras-Antolin L. The burden of Neonatal Invasive Candidiasis in Low- and Middle-Income Countries: a systematic review and meta-analysis. Open Forum Infectious Diseases. 2025 Jun 11;12(7):ofaf329.
-
Drug RepurposingTsai DHT, Chuang ATM, Liu KH, Shao SC, Lai ECC. Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease. CMAJ. 2025 Feb 23;197(7):E178-E189.
-
Data InfrastructureTsai DHT, Bell JS, Abtahi S, Baak BN, Bazelier MT, Brauer R, Chan AYL, Chan EW, Chen H, Chui CSL, Cook S, Crystal S, Gandhi P, Hartikainen S, Ho FK, Hsu ST, Ilomäki J, Kim JH, Klungel OH, Koponen M, Lau WCY, Lau KK, Lum TYS, Luo H, Man KKC, Pell JP, Setoguchi S, Shao SC, Shen CY, Shin JY, Souverein PC, Tolppanen AM, Wei L, Wong ICK, Lai ECC. Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders. Clinical Epidemiology. 2023 Dec 21;15:1241-1252.
-
PolypharmacyHuang WC, Yang ASH, Tsai DHT, Shao SC, Lin SJ, Lai ECC. Association between recently elevated anticholinergic burden and risk of acute cardiovascular events: A nationwide case-case-time-control study. The BMJ. 2023 Sep 27;382:e076045.
